vs

Side-by-side financial comparison of BATTALION OIL CORP (BATL) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

BATTALION OIL CORP is the larger business by last-quarter revenue ($31.6M vs $19.6M, roughly 1.6× STANDARD BIOTOOLS INC.). BATTALION OIL CORP runs the higher net margin — 5.7% vs -177.4%, a 183.1% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -36.1%). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -20.1%).

Battalion Oil Corp is an independent energy company engaged in the exploration, development, and production of crude oil, natural gas, and natural gas liquids. It primarily operates assets in the Eagle Ford Shale region of South Texas, serving commercial and industrial clients across North American energy markets.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BATL vs LAB — Head-to-Head

Bigger by revenue
BATL
BATL
1.6× larger
BATL
$31.6M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+24.7% gap
LAB
-11.5%
-36.1%
BATL
Higher net margin
BATL
BATL
183.1% more per $
BATL
5.7%
-177.4%
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-20.1%
BATL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BATL
BATL
LAB
LAB
Revenue
$31.6M
$19.6M
Net Profit
$1.8M
$-34.7M
Gross Margin
48.5%
Operating Margin
-33.8%
-168.5%
Net Margin
5.7%
-177.4%
Revenue YoY
-36.1%
-11.5%
Net Profit YoY
108.1%
-28.8%
EPS (diluted)
$-0.77
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BATL
BATL
LAB
LAB
Q4 25
$31.6M
Q3 25
$43.4M
$19.6M
Q2 25
$42.6M
$21.8M
Q1 25
$47.4M
$40.8M
Q4 24
$49.5M
Q3 24
$45.1M
$22.1M
Q2 24
$49.1M
$22.5M
Q1 24
$49.5M
$45.5M
Net Profit
BATL
BATL
LAB
LAB
Q4 25
$1.8M
Q3 25
$-735.0K
$-34.7M
Q2 25
$4.8M
$-33.5M
Q1 25
$6.0M
$-26.0M
Q4 24
$-22.2M
Q3 24
$21.6M
$-26.9M
Q2 24
$-105.0K
$-45.7M
Q1 24
$-31.2M
$-32.2M
Gross Margin
BATL
BATL
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
BATL
BATL
LAB
LAB
Q4 25
-33.8%
Q3 25
1.9%
-168.5%
Q2 25
-0.4%
-118.1%
Q1 25
7.2%
-80.8%
Q4 24
-36.2%
Q3 24
2.3%
-120.9%
Q2 24
10.4%
-134.5%
Q1 24
0.0%
-132.2%
Net Margin
BATL
BATL
LAB
LAB
Q4 25
5.7%
Q3 25
-1.7%
-177.4%
Q2 25
11.3%
-153.7%
Q1 25
12.7%
-63.8%
Q4 24
-44.9%
Q3 24
48.0%
-122.0%
Q2 24
-0.2%
-203.3%
Q1 24
-63.0%
-70.6%
EPS (diluted)
BATL
BATL
LAB
LAB
Q4 25
$-0.77
Q3 25
$-0.91
$-0.09
Q2 25
$-0.21
$-0.09
Q1 25
$-0.35
$-0.07
Q4 24
$-1.47
Q3 24
$0.34
$-0.07
Q2 24
$-0.53
$-0.12
Q1 24
$-2.24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BATL
BATL
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$28.0M
$129.4M
Total DebtLower is stronger
$208.1M
Stockholders' EquityBook value
$-32.8M
$399.7M
Total Assets
$460.7M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BATL
BATL
LAB
LAB
Q4 25
$28.0M
Q3 25
$50.5M
$129.4M
Q2 25
$44.6M
$158.6M
Q1 25
$73.6M
$150.9M
Q4 24
$19.7M
Q3 24
$29.8M
$210.6M
Q2 24
$54.4M
$269.8M
Q1 24
$48.9M
$287.1M
Total Debt
BATL
BATL
LAB
LAB
Q4 25
$208.1M
Q3 25
$213.8M
Q2 25
$219.4M
Q1 25
$225.1M
Q4 24
$162.1M
Q3 24
$147.8M
$55.2M
Q2 24
$160.4M
$55.1M
Q1 24
$190.2M
$55.0M
Stockholders' Equity
BATL
BATL
LAB
LAB
Q4 25
$-32.8M
Q3 25
$-20.3M
$399.7M
Q2 25
$-5.2M
$424.5M
Q1 25
$-1.8M
$454.6M
Q4 24
$4.1M
Q3 24
$35.0M
$489.3M
Q2 24
$22.7M
$510.3M
Q1 24
$31.3M
$577.3M
Total Assets
BATL
BATL
LAB
LAB
Q4 25
$460.7M
Q3 25
$491.7M
$539.6M
Q2 25
$498.8M
$557.0M
Q1 25
$506.2M
$579.6M
Q4 24
$431.0M
Q3 24
$458.0M
$681.5M
Q2 24
$487.3M
$708.7M
Q1 24
$488.6M
$777.7M
Debt / Equity
BATL
BATL
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
39.35×
Q3 24
4.23×
0.11×
Q2 24
7.07×
0.11×
Q1 24
6.07×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BATL
BATL
LAB
LAB
Operating Cash FlowLast quarter
$-11.8M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
-6.58×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BATL
BATL
LAB
LAB
Q4 25
$-11.8M
Q3 25
$28.0M
$-22.2M
Q2 25
$10.2M
$-20.7M
Q1 25
$12.7M
$-30.3M
Q4 24
$6.7M
Q3 24
$-5.1M
$-27.9M
Q2 24
$29.8M
$-39.0M
Q1 24
$3.9M
$-62.5M
Free Cash Flow
BATL
BATL
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
BATL
BATL
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
BATL
BATL
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
BATL
BATL
LAB
LAB
Q4 25
-6.58×
Q3 25
Q2 25
2.13×
Q1 25
2.11×
Q4 24
Q3 24
-0.23×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BATL
BATL

Oil$28.6M91%
Natural Gas Liquids Reserves$3.9M12%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons